NASDAQ:CING Cingulate - CING Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.98 -0.04 (-3.90%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.98▼$1.0650-Day Range$0.91▼$1.8552-Week Range$0.66▼$2.04Volume53,730 shsAverage Volume435,590 shsMarket Capitalization$11.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Cingulate (NASDAQ:CING) StockCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address CING Stock News HeadlinesMarch 15, 2023 | msn.comCingulate stock slumps ~15% on commercialization pact for ADHD drug CTx-1301March 13, 2023 | msn.comCingulate Tanks on Teaming Up with Indegene for ADHD DrugApril 1, 2023 | Vantage Point (Ad)What To Do With Your Trades TodayThere’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts March 13, 2023 | bizjournals.comCingulate signs agreement to market its first drug candidateMarch 13, 2023 | finance.yahoo.comCingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301March 10, 2023 | finance.yahoo.comCingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business UpdateMarch 10, 2023 | marketwatch.comCingulate Shares Slide 19% on Stock OfferingMarch 10, 2023 | finance.yahoo.comCingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business UpdateApril 1, 2023 | Vantage Point (Ad)What To Do With Your Trades TodayThere’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts March 9, 2023 | msn.comInformation overload: Is all this technology bad for your brain?March 9, 2023 | benzinga.comEVP and COO at Cingulate Acquires Company Stock Options Worth 40,000 SharesMarch 9, 2023 | benzinga.comCingulate Chief Executive Officer Awarded $126K Worth of Stock OptionsMarch 5, 2023 | msn.comNew remains of multiple extinct species excavated on Chilean coastMarch 4, 2023 | finance.yahoo.comWhy Cingulate Shares Are Trading Higher TodayMarch 3, 2023 | msn.comWhat Is the Default Mode Network?February 24, 2023 | msn.comCingulate Pops after Positive Topline DataFebruary 24, 2023 | benzinga.comThinking about buying stock in Beyond Meat, ACM Research, Farfetch, Protalix Biotherapeutics, or Cingulate?February 24, 2023 | finance.yahoo.comCingulate stock skyrockets after ADHD treatment shows positive trial resultsFebruary 24, 2023 | investorplace.comWhy Is Cingulate (CING) Stock Up 72% Today?February 24, 2023 | msn.comHUMBL stock dips 2%, cancels reverse stock splitFebruary 23, 2023 | msn.comCingulate pops ~76% after hours on trial results for its ADHD treatment drugFebruary 23, 2023 | finance.yahoo.comCingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset CTx-1301 for ADHDFebruary 16, 2023 | msn.comRacism takes a toll on the brain, research showsFebruary 15, 2023 | marketwatch.comPostpartum Depression Management Market Share, Size, Share, Industry Trends, Demand, Overview and Forecast 2022 to 2028February 11, 2023 | msn.comResearchers identify a potential neural signature of social belongingFebruary 10, 2023 | msn.comObese individuals have reduced grey matter density and functional brain abnormalities, study findsFebruary 3, 2023 | msn.comCan Ketamine alleviate depression from chronic pain?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address CING Company Calendar Today4/01/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-174.78% Return on Assets-119.80% Debt Debt-to-Equity Ratio0.01 Current Ratio1.12 Quick Ratio1.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book2.90Miscellaneous Outstanding Shares11,310,000Free Float7,772,000Market Cap$11.14 million OptionableNot Optionable Beta0.06 Key ExecutivesDr. Shane J. Schaffer Pharm.D. (Age 48)PharmD, CEO & Chairman Comp: $475kMr. Louis G. Van Horn CPA (Age 64)M.B.A., Exec. VP & CFO Comp: $380kDr. Laurie A. Myers M.B.A. (Age 66)Ph.D., Exec. VP & COO Comp: $400kMr. Craig S. Gilgallon Esq. (Age 50)Exec. VP, Gen. Counsel & Board Sec. Comp: $380kDr. Raul R. Silva M.D. (Age 65)Exec. VP & Chief Science Officer Thomas DaltonHead of Investor & PRDr. Matthew N. Brams M.D. (Age 59)Exec. VP & Chief Medical Officer More ExecutivesKey CompetitorsApexigenNASDAQ:APGNVascular BiogenicsNASDAQ:VBLTLiminal BioSciencesNASDAQ:LMNLRedHill BiopharmaNASDAQ:RDHLAptorum GroupNASDAQ:APMView All CompetitorsInsiders & InstitutionsHighTower Advisors LLCBought 34,425 shares on 2/9/2023Ownership: 0.304%Shane J SchafferBought 10,000 shares on 12/16/2022Total: $10,200.00 ($1.02/share)Jennifer L CallahanBought 7,548 shares on 12/14/2022Total: $7,472.52 ($0.99/share)Peter J WerthBought 28,934 shares on 12/13/2022Total: $28,355.32 ($0.98/share)Shane J SchafferBought 1,733 shares on 12/13/2022Total: $1,750.33 ($1.01/share)View All Insider TransactionsView All Institutional Transactions CING Stock - Frequently Asked Questions Should I buy or sell Cingulate stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CING shares. View CING analyst ratings or view top-rated stocks. How have CING shares performed in 2023? Cingulate's stock was trading at $1.00 at the beginning of the year. Since then, CING shares have decreased by 1.5% and is now trading at $0.9850. View the best growth stocks for 2023 here. Are investors shorting Cingulate? Cingulate saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 404,000 shares, a decline of 62.2% from the February 28th total of 1,070,000 shares. Based on an average daily volume of 848,400 shares, the days-to-cover ratio is presently 0.5 days. Currently, 5.3% of the shares of the company are sold short. View Cingulate's Short Interest. When is Cingulate's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our CING earnings forecast. When did Cingulate IPO? (CING) raised $29 million in an IPO on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share. What is Cingulate's stock symbol? Cingulate trades on the NASDAQ under the ticker symbol "CING." How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cingulate's stock price today? One share of CING stock can currently be purchased for approximately $0.99. How much money does Cingulate make? Cingulate (NASDAQ:CING) has a market capitalization of $11.14 million. The company earns $-17,680,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. How can I contact Cingulate? The official website for the company is www.cingulate.com. The company can be reached via phone at 913-942-2300 or via email at ir@cingulate.com. This page (NASDAQ:CING) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.